Scribe Therapeutics, Inc.

General form for quarterly reports under Section 13 or 15(d)

Results of Operations and Financial Condition

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement with Pricing Information

Free Writing Prospectus

Notice of Effectiveness

No description available

Certification of approval for listing and registration on a national securities exchange

Registration of Securities on Exchange

Amended Initial Registration Statement

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Draft registration statement (confidential submission) (amendment)

Draft registration statement (confidential submission) (amendment)

Draft registration statement (confidential submission)

06b

GORDON CARL L

Andreessen Marc L; HOROWITZ BENJAMIN A; AH Bio Fund II, L.P.; AH Equity Partners Bio II, L.L.C.; AH Bio Fund III, L.P.; AH Equity Partners Bio III, L.L.C.

ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC

Doudna Jennifer A

Staahl Brett

Avoro Capital Advisors LLC; Avoro Ventures LLC; Aghazadeh Behzad

Bleharski Joshua

Lucas Svetlana

Oakes Benjamin L.

Parrot David

Watson James Dean

GORDON CARL L

Avoro Capital Advisors LLC; Avoro Ventures LLC; Aghazadeh Behzad

ELI LILLY & Co

Avoro Capital Advisors LLC; Avoro Ventures LLC; Aghazadeh Behzad

ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC